CeO2@NH2 functionalized electrodes for the rapid detection of SARS-CoV-2 spike receptor binding domain. Issue 9 (16th February 2023)

• Record Type: Journal Article
• Authors: Triastuti, Ayu; Zakiyyah, Salma Nur; Gaffar, Shabarni; Anshori, Isa; Surawijaya, Akhmadi; Hidayat, Darmawan; Wiraswati, Hesti Lina; Yusuf, Muhammad; Hartati, Yeni Wahyuni
• Is Part Of: RSC advances. Volume 13:Issue 9(2023)
• Page Start: 5874
• Page End: 5884
• Publication Date: 2023-02-16
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d2ra07560a
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : A detection method based on an electrochemical aptasensor has been developed as an alternative fast, portable, simple, inexpensive, and high-accuracy detection method for detecting the SARS-CoV-2 Spike Receptor Binding Domain (spike RBD). Abstract : A detection method based on an electrochemical aptasensor has been developed as an alternative fast, portable, simple, inexpensive, and high-accuracy detection method for detecting the SARS-CoV-2 Spike Receptor Binding Domain (spike RBD). The CeO2 @NH2 functionalized Screen Printed Carbon Electrode (SPCE) was used to immobilize an aminated aptamer of spike RBD protein via glutaraldehyde as a linker. The aptamer's interaction with the SARS-CoV-2 Spike RBD was measured via the [Fe(CN)6 ] 4−/3− redox system signal. Experimental conditions were optimized using a Box–Behnken experimental design and showed that the optimal conditions of the SARS-CoV-2 aptasensor were 1.5 ng mL −1 of aptamer, immobilization of aptamer for 60 minutes, and Spike RBD incubation for 10 minutes. The developed aptasensor was able to detect the standard SARS-CoV-2 Spike RBD with a detection limit of 0.017 ng mL −1 in the range of 0.001–100 ng mL −1 . This aptasensor was used to detect salivary and oropharyngeal swab samples of normal individuals with the addition of Spike RBD, and the recoveries were 92.96% and 96.52%, respectively. The testing on nasopharyngeal swab samples of COVID-19 patients showed that the aptasensor results were comparable with the qRT-PCR results. Thus, the developed aptasensor has the potential to be applied as a SARS-CoV-2 rapid test method for clinical samples.